197 related articles for article (PubMed ID: 35752223)
1. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies.
Lampertico P; Roulot D; Wedemeyer H
J Hepatol; 2022 Nov; 77(5):1422-1430. PubMed ID: 35752223
[TBL] [Abstract][Full Text] [Related]
2. Bulevirtide for patients with compensated chronic hepatitis delta: A review.
Degasperi E; Anolli MP; Lampertico P
Liver Int; 2023 Aug; 43 Suppl 1():80-86. PubMed ID: 35942695
[TBL] [Abstract][Full Text] [Related]
3. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.
Degasperi E; Anolli MP; Uceda Renteria SC; Sambarino D; Borghi M; Perbellini R; Scholtes C; Facchetti F; Loglio A; Monico S; Fraquelli M; Costantino A; Ceriotti F; Zoulim F; Lampertico P
J Hepatol; 2022 Dec; 77(6):1525-1531. PubMed ID: 35973578
[TBL] [Abstract][Full Text] [Related]
4. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
Allweiss L; Volmari A; Suri V; Wallin JJ; Flaherty JF; Manuilov D; Downie B; Lütgehetmann M; Bockmann JH; Urban S; Wedemeyer H; Dandri M
J Hepatol; 2024 Jun; 80(6):882-891. PubMed ID: 38340811
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; Scholtes C; Holzmann H; van Bömmel F; Borghi M; Perbellini R; Rimondi A; Farina E; Trombetta E; Manunta M; Porretti L; Prati D; Ceriotti F; Zoulim F; Bertoletti A; Lampertico P
J Hepatol; 2022 Feb; 76(2):464-469. PubMed ID: 34699951
[TBL] [Abstract][Full Text] [Related]
6. Bulevirtide: First Approval.
Kang C; Syed YY
Drugs; 2020 Oct; 80(15):1601-1605. PubMed ID: 32926353
[TBL] [Abstract][Full Text] [Related]
7. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life.
Asselah T; Loureiro D; Le Gal F; Narguet S; Brichler S; Bouton V; Abazid M; Boyer N; Giuly N; Gerber A; Tout I; Maylin S; Bed CM; Marcellin P; Castelnau C; Gordien E; Mansouri A
Liver Int; 2021 Jul; 41(7):1509-1517. PubMed ID: 33999515
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis].
Bogomolov PO; Ivashkin VT; Bueverov AO; Maev IV; Sagalova OI; Sleptsova SS; Yushuk ND; Gusev DA; Zhdanov KV; Chulanov VP
Ter Arkh; 2021 Nov; 93(11):1290-1299. PubMed ID: 36286651
[TBL] [Abstract][Full Text] [Related]
9. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.
Jachs M; Schwarz C; Panzer M; Binter T; Aberle SW; Hartl L; Dax K; Aigner E; Stättermayer AF; Munda P; Graziadei I; Holzmann H; Trauner M; Zoller H; Gschwantler M; Mandorfer M; Reiberger T; Ferenci P
Aliment Pharmacol Ther; 2022 Jul; 56(1):144-154. PubMed ID: 35514008
[TBL] [Abstract][Full Text] [Related]
10. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
Deterding K; Wedemeyer H
AIDS Rev; 2019; 21(3):126-134. PubMed ID: 31532397
[TBL] [Abstract][Full Text] [Related]
11. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; van Bömmel F; Borghi M; Holzmann H; Perbellini R; Trombetta E; Giovanelli S; Greco L; Porretti L; Prati D; Ceriotti F; Lunghi G; Bertoletti A; Lampertico P
J Hepatol; 2019 Oct; 71(4):834-839. PubMed ID: 31302176
[TBL] [Abstract][Full Text] [Related]
12. HBV/HDV Coinfection: A Challenge for Therapeutics.
Koh C; Da BL; Glenn JS
Clin Liver Dis; 2019 Aug; 23(3):557-572. PubMed ID: 31266627
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
Bogomolov P; Alexandrov A; Voronkova N; Macievich M; Kokina K; Petrachenkova M; Lehr T; Lempp FA; Wedemeyer H; Haag M; Schwab M; Haefeli WE; Blank A; Urban S
J Hepatol; 2016 Sep; 65(3):490-8. PubMed ID: 27132170
[TBL] [Abstract][Full Text] [Related]
14. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase 3 randomized trial.
Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Ciesek S; Manuilov D; Mercier RC; Da BL; Chee GM; Li M; Flaherty JF; Lau AH; Osinusi A; Schulze Zur Wiesch J; Cornberg M; Zeuzem S; Lampertico P
J Hepatol; 2024 May; ():. PubMed ID: 38734383
[TBL] [Abstract][Full Text] [Related]
15. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
[TBL] [Abstract][Full Text] [Related]
16. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of the Peginterferon treatment in chronic hepatitis HDV and compensate liver cirrhosis.
Tugui L; Dumitru M; Iacob S; Gheorghe L; Preda C; Dinu I; Becheanu G; Dumbrava M; Nicolae I; Andrei A; Lupu A; Diculescu M
Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):368-75. PubMed ID: 25076702
[TBL] [Abstract][Full Text] [Related]
18. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect].
Nkongolo S; Hollnberger J; Urban S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Feb; 65(2):254-263. PubMed ID: 35028672
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
20. Chronic hepatitis D-What is changing?
Yardeni D; Heller T; Koh C
J Viral Hepat; 2022 Apr; 29(4):240-251. PubMed ID: 35122369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
